Linker-drug and antibody-drug conjugate (ADC) employing the same
US10864279B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 4, 2017 |
| Grant date | Dec 15, 2020 |
| Priority date | — |
| Expiry date | Dec 4, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/65
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A linker-drug represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), C is a conjugator, L is a linker unit, D is a toxin unit, and n is an integer ranging from 1 to 4. The structure of the conjugator is represented by formula (II). In formula (II), X is a leaving group, each of R1 and R2 is independently a single bond or —NH—, and Z is substituted aryl, heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or a combination thereof. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. An antibody-drug conjugate (ADC) employing the above linker-drug is also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.